Skip to content

An applied research on PSMA PET/CT and 18F-FDG PET/CT in diagnosis and treatment of renal tumors

An applied research on PSMA PET/CT and 18F-FDG PET/CT in diagnosis and treatment of renal tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044927
Enrollment
Unknown
Registered
2021-03-31
Start date
2021-03-30
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal tumor

Interventions

Sponsors

Department of urology, The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. PSMA PET/CT+18F-FDG PET/CT was performed within 30 days before surgery in our hospital; 2. Complete preoperative and postoperative clinicopathological data; 3. Comprehensive clinical evaluation of patients undergoing partial nephrectomy or radical nephrectomy.

Exclusion criteria

Exclusion criteria: 1. Patients who have received radiotherapy, chemotherapy, immunotherapy and other tumor adjuvant treatments before surger; 2. No surgical treatment; 3. Patients who have contraindications to the tracer and can't complete the follow-up review.

Design outcomes

Primary

MeasureTime frame
Pathological type of tumor;Tumor volume;Sarcomatoid changes of the tumor;Tumor necrosis ratio;Fuhrman grade of tumor;Age;Body Mass Index;Patient survival situation;Maximal standard uptake value;Mean standard uptake value;Metabolic tumor volume;Total lesion glycolysis;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactXu Ning

The First Affiliated Hospital of Fujian Medical University

drxun@fjmu.edu.cn+86 13235907575

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026